Astellas Pharma Inc.

TSE:4503 Stock Report

Market Cap: JP¥2.9t

Astellas Pharma Past Earnings Performance

Past criteria checks 3/6

Astellas Pharma's earnings have been declining at an average annual rate of -24%, while the Pharmaceuticals industry saw earnings growing at 5.1% annually. Revenues have been growing at an average rate of 10.3% per year. Astellas Pharma's return on equity is 7.7%, and it has net margins of 6.2%.

Key information

-24.00%

Earnings growth rate

-23.18%

EPS growth rate

Pharmaceuticals Industry Growth3.41%
Revenue growth rate10.26%
Return on equity7.74%
Net Margin6.22%
Last Earnings Update30 Sep 2025

Recent past performance updates

Statutory Profit Doesn't Reflect How Good Astellas Pharma's (TSE:4503) Earnings Are

May 08
Statutory Profit Doesn't Reflect How Good Astellas Pharma's (TSE:4503) Earnings Are

Recent updates

Astellas Pharma Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Nov 03
Astellas Pharma Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Astellas Pharma's (TSE:4503) Upcoming Dividend Will Be Larger Than Last Year's

Sep 19
Astellas Pharma's (TSE:4503) Upcoming Dividend Will Be Larger Than Last Year's

Astellas Pharma's (TSE:4503) Upcoming Dividend Will Be Larger Than Last Year's

Aug 12
Astellas Pharma's (TSE:4503) Upcoming Dividend Will Be Larger Than Last Year's

Astellas Pharma Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Aug 01
Astellas Pharma Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Astellas Pharma (TSE:4503) Is Increasing Its Dividend To ¥39.00

Jul 24
Astellas Pharma (TSE:4503) Is Increasing Its Dividend To ¥39.00

Astellas Pharma (TSE:4503) Is Paying Out A Larger Dividend Than Last Year

Jul 10
Astellas Pharma (TSE:4503) Is Paying Out A Larger Dividend Than Last Year

Astellas Pharma Inc.'s (TSE:4503) P/E Is On The Mark

Jun 20
Astellas Pharma Inc.'s (TSE:4503) P/E Is On The Mark

Statutory Profit Doesn't Reflect How Good Astellas Pharma's (TSE:4503) Earnings Are

May 08
Statutory Profit Doesn't Reflect How Good Astellas Pharma's (TSE:4503) Earnings Are

Astellas Pharma Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Apr 29
Astellas Pharma Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

These 4 Measures Indicate That Astellas Pharma (TSE:4503) Is Using Debt Reasonably Well

Mar 13
These 4 Measures Indicate That Astellas Pharma (TSE:4503) Is Using Debt Reasonably Well

Astellas Pharma (TSE:4503) Is Due To Pay A Dividend Of ¥37.00

Feb 15
Astellas Pharma (TSE:4503) Is Due To Pay A Dividend Of ¥37.00

Astellas Pharma Inc. Just Missed Earnings; Here's What Analysts Are Forecasting Now

Feb 07
Astellas Pharma Inc. Just Missed Earnings; Here's What Analysts Are Forecasting Now

Astellas Pharma (TSE:4503) Has Announced A Dividend Of ¥37.00

Feb 01
Astellas Pharma (TSE:4503) Has Announced A Dividend Of ¥37.00

Astellas Pharma (TSE:4503) Has Announced A Dividend Of ¥37.00

Jan 17
Astellas Pharma (TSE:4503) Has Announced A Dividend Of ¥37.00

Astellas Pharma (TSE:4503) Has Announced A Dividend Of ¥37.00

Jan 03
Astellas Pharma (TSE:4503) Has Announced A Dividend Of ¥37.00
User avatar

Strategic Brands XTANDI And PADCEV Ignite Growth And Boost Margins In Pharma Innovator

Strategic brand growth and expanded product indications are driving revenue and upward revisions in forecasts, particularly in key markets like the U.S.

Astellas Pharma (TSE:4503) Will Pay A Dividend Of ¥37.00

Dec 04
Astellas Pharma (TSE:4503) Will Pay A Dividend Of ¥37.00

Astellas Pharma's (TSE:4503) Earnings May Just Be The Starting Point

Nov 06
Astellas Pharma's (TSE:4503) Earnings May Just Be The Starting Point

Revenue & Expenses Breakdown

How Astellas Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

TSE:4503 Revenue, expenses and earnings (JPY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 252,006,816124,871840,455298,610
30 Jun 251,944,99381,566833,152312,528
31 Mar 251,912,32350,747843,032327,651
31 Dec 241,867,631-57,427821,251329,275
30 Sep 241,772,15554,746799,059324,570
30 Jun 241,701,80621,519775,191316,416
31 Mar 241,603,67217,045740,110294,187
31 Dec 231,543,3244,198706,256286,410
30 Sep 231,523,57238,090669,778278,898
30 Jun 231,511,818107,031645,058266,713
31 Mar 231,518,61998,714630,272276,128
31 Dec 221,468,235136,430613,397274,414
30 Sep 221,406,682148,911586,290266,127
30 Jun 221,351,811118,211565,127261,704
31 Mar 221,296,163124,086548,840246,010
31 Dec 211,300,914120,167547,692233,316
30 Sep 211,285,714119,360532,687231,849
30 Jun 211,268,702100,863520,649225,514
31 Mar 211,249,528120,589504,316224,489
31 Dec 201,253,215138,307508,764233,293
30 Sep 201,265,853139,722515,363230,952
30 Jun 201,273,678187,306502,601228,007
31 Mar 201,300,843195,411499,295224,226
31 Dec 191,289,855220,751488,054218,477
30 Sep 191,309,722246,925484,800214,090
30 Jun 191,311,397226,224494,845210,057
31 Mar 191,306,348222,265490,263208,682
31 Dec 181,305,901213,600484,099209,117
30 Sep 181,307,658186,429481,546212,867
30 Jun 181,306,830176,770478,883216,436
31 Mar 181,300,316164,679478,330220,781
31 Dec 171,305,521182,515484,126221,463
30 Sep 171,299,746185,754478,249215,938
30 Jun 171,296,484194,556471,227213,584
31 Mar 171,311,665218,701470,777208,129
31 Dec 161,312,627207,940474,335208,958
30 Sep 161,336,878205,818481,460213,295
30 Jun 161,366,799215,678493,582220,707
31 Mar 161,372,706193,687500,359225,665
31 Dec 151,360,153185,659497,984223,590
30 Sep 151,340,307168,805490,493221,608
30 Jun 151,295,761144,617474,276214,931
31 Mar 151,247,259135,856452,522206,594
31 Dec 141,205,276124,154251,755339,460

Quality Earnings: 4503 has a large one-off loss of ¥169.5B impacting its last 12 months of financial results to 30th September, 2025.

Growing Profit Margin: 4503's current net profit margins (6.2%) are higher than last year (3.1%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 4503's earnings have declined by 24% per year over the past 5 years.

Accelerating Growth: 4503's earnings growth over the past year (128.1%) exceeds its 5-year average (-24% per year).

Earnings vs Industry: 4503 earnings growth over the past year (128.1%) exceeded the Pharmaceuticals industry 9.6%.

Return on Equity

High ROE: 4503's Return on Equity (7.7%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/02 10:42
End of Day Share Price 2025/10/31 00:00
Earnings2025/09/30
Annual Earnings2025/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Astellas Pharma Inc. is covered by 25 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Atsushi SekiBarclays
Koichi MameganoBofA Global Research
Hidemaru YamaguchiCitigroup Inc